Sutro Biopharma Q2 EPS $(0.64) Beats $(0.73) Estimate, Sales $10.41M Miss $12.56M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sutro Biopharma reported Q2 losses of $(0.64) per share, beating the analyst consensus estimate of $(0.73) by 12.33%. However, the company's quarterly sales of $10.41 million missed the analyst consensus estimate of $12.56 million by 17.10%. This represents a 62.94% decrease over sales from the same period last year.
August 10, 2023 | 8:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sutro Biopharma's Q2 earnings beat estimates but sales missed, indicating mixed performance. This could lead to uncertainty among investors.
Sutro Biopharma's Q2 earnings beat analyst estimates, which is a positive signal. However, the company's sales missed estimates and decreased significantly compared to the same period last year. This mixed performance could lead to uncertainty among investors, potentially impacting the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100